

Strictly private and confidential

October 13, 2021

## FNM S.p.A Issuance of EUR 650,000,000 0.750 per cent. Notes due 2026

## under the Euro 1,000,000,000 Euro Medium Term Note Programme

## Term Sheet

lssuer:	FNM S.p.A (the "Issuer")
Issuer's ratings:	Baa3 stable (Moody's) / BBB- stable (Fitch)
Issue's expected ratings:	Baa3 (Moody's) / BBB- (Fitch)
Nominal Amount:	EUR 650,000,000
Joint Bookrunners:	BNP Paribas Intesa Sanpaolo (B&D) J.P. Morgan
Co-Lead Managers:	Equita SIM
Announcement Date:	October 13, 2021
Settlement Date:	October 20, 2021
Maturity Date:	October 20, 2026
Coupon:	0.750%
Interest Payment Dates:	Annually in arrears on October 20, starting from October 20, 2022, and each year thereafter until, and including, the Maturity Date
Day Count Fraction:	Actual/Actual (ICMA)
Benchmark:	DBR 0.000% Aug-26 @ 102.510 (DE0001102408)
Spread to benchmark:	129.8bps
Spread vs. Mid-Swap / Mid-Swap:	88bps / -0.094%
Re-offer yield:	0.786%
Re-offer price:	99.824%
Fees:	0.60 per cent of Nominal Amount upfront to be divided equally between each Joint Bookrunner
	0.05 per cent of Nominal Amount upfront to be divided equally between each Co-Lead Manager
All-in price:	99.174%
Net proceeds:	EUR 644,631,000

Strictly private and confidential



Redemption Price:	100%
Call Options:	Issuer Call at Make-Whole Amount @ (Benchmark + 20bps) Clean-Up Call Option @ 80% Issuer Maturity 3m Par Call
Use of Proceeds:	Refinancing of existing indebtedness and general corporate purposes
Listing:	Irish Stock Exchange (regulated market)
Clearing:	Euroclear / Clearstream
Denominations:	€100,000 and integral multiples of €1,000 in excess thereof
Status of the Notes:	Senior Notes, constituting direct, unconditional, unsecured and unsubordinated obligations of the Issuer and ranking <i>pari passu</i> without any preference among themselves
Form of Notes:	Bearer
Type of Notes:	New Global Note
Governing law:	English law
ISIN / Commo Code :	XS2400296773 / 240029677
Documentation:	As per the Euro Medium Term Note Programme dated September 28, 2021, including, inter alia, legal opinions, comfort letter and management due diligence call satisfactory to the Joint Bookrunners
Selling restrictions:	Reg S, US, UK and as per the Base Prospectus dated September 28, 2021
.Target Market:	Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail in EEA
Expenses:	The Issuer is responsible for all the expenses including legal expenses of the Joint Bookrunners, listing, printing, fiscal and paying agency



## Disclaimer

This term sheet has been prepared by the Joint Bookrunners for information purposes only. This term sheet is for discussion purposes only and is not intended to create any legally binding obligations. The type of transaction described in this document may not be suitable for you. Please take your own independent professional advice in order to assess if this type of transaction is appropriate for you given your circumstances and objectives. Before entering into any transaction you should ensure that you fully understand its potential risks and rewards and independently determine that it is appropriate for you given your objectives, experience, financial and operational resources. No representation or warranty is made that any indicative performance or return indicated will be achieved in the future. The Joint Bookrunners are not acting as your financial, legal, tax or other adviser or in any fiduciary capacity, and this document does not constitute advice, or an offer (of any type), invitation to offer or recommendation, to you. If after making your own assessment you independently decide you would like to pursue a specific transaction with us there will be separate legal documentation, the terms of which will (if agreed) supersede any indicative and summary terms contained in this document. The Joint Bookrunners therefore do not accept any liability for any direct, consequential or other loss arising from reliance on this document. The Joint Bookrunners may maintain positions in the products referred to herein, or be engaged in other transactions involving these products and/or earn brokerage and fees etc. This document is confidential and may not be distributed (in whole or in part) to any other person, save for your professional or other advisers, (to whom we shall owe no duty of care) without the prior written permission of the Joint Bookrunners. This term sheet is only for the information of the issuer and the Joint Bookrunners and is not for, and may not be relied upon, by any investor or any other person for any purpose. We make no representation as to the completeness or accuracy of the information contained in this document. No offering of securities shall be made in the United States except pursuant to registration under the United States Securities Act of 1933 (as amended the "Act") or any exemption from such registration provided by Rule 144A or Regulation S of the Act. In addition, the provision of investment services may be restricted in certain jurisdictions.